Poor rates of minority participation in cancer clinical trials, and inequitable distribution of results from clinical research contribute to persistent disparities in cancer care outcomes. Systematic reviews of minority participation in clinical research reveal extensive research on patient and provider-level barriers to participation in clinical trials; however, there is limited research on the organizational drivers of minority enrollment in clinical treatment trials. The goal of this dissertation is to enhance our understanding of the organizational determinants of minority participation in cancer treatment trials. The objectives of this dissertation are: (1) estimate the impact of organizational characteristics associated with black enr...
There is increasing evidence that societal inequities and cultural differences in attitudes toward c...
Research has shown that there continues to be insufficient recruitment of minorities in clinical tri...
Racial/ethnic disparities in breast cancer outcomes have been well documented; however, the reasons ...
Poor rates of minority participation in cancer clinical trials, and inequitable distribution of resu...
Background. Black patients in the U.S. receive fewer cancer treatment cycles than White patients on ...
Background: Study populations in clinical research must reflect US changing demographics, especially...
Participation in cancer clinical trials (CCTs) is an effective means of reducing cancer disparities ...
Background: Racial and ethnic minority groups (REMGs) have low rates of inclusion in cancer trials. ...
PURPOSE:: Participation of racial and ethnic minority groups (REMGs) in cancer trials is disproporti...
Background: Despite the promising effectiveness of clinical trials on breast cancer prevention, trea...
BACKGROUND: Studies using administrative data report that racial/ethnic minority patients enroll in ...
Cancer clinical trials are important for resolving cancer health disparities for several reasons; ho...
The underrepresentation of minorities has received considerable attention since the 1990s when NIH r...
BackgroundStudy populations in clinical research must reflect US changing demographics, especially w...
Racial and ethnic diversity has historically been difficult to achieve in National Cancer Institute-...
There is increasing evidence that societal inequities and cultural differences in attitudes toward c...
Research has shown that there continues to be insufficient recruitment of minorities in clinical tri...
Racial/ethnic disparities in breast cancer outcomes have been well documented; however, the reasons ...
Poor rates of minority participation in cancer clinical trials, and inequitable distribution of resu...
Background. Black patients in the U.S. receive fewer cancer treatment cycles than White patients on ...
Background: Study populations in clinical research must reflect US changing demographics, especially...
Participation in cancer clinical trials (CCTs) is an effective means of reducing cancer disparities ...
Background: Racial and ethnic minority groups (REMGs) have low rates of inclusion in cancer trials. ...
PURPOSE:: Participation of racial and ethnic minority groups (REMGs) in cancer trials is disproporti...
Background: Despite the promising effectiveness of clinical trials on breast cancer prevention, trea...
BACKGROUND: Studies using administrative data report that racial/ethnic minority patients enroll in ...
Cancer clinical trials are important for resolving cancer health disparities for several reasons; ho...
The underrepresentation of minorities has received considerable attention since the 1990s when NIH r...
BackgroundStudy populations in clinical research must reflect US changing demographics, especially w...
Racial and ethnic diversity has historically been difficult to achieve in National Cancer Institute-...
There is increasing evidence that societal inequities and cultural differences in attitudes toward c...
Research has shown that there continues to be insufficient recruitment of minorities in clinical tri...
Racial/ethnic disparities in breast cancer outcomes have been well documented; however, the reasons ...